Identification of small molecules and related targets that modulate tau pathology in a seeded primary neuron model

Alzheimer's disease (AD) is characterized by the presence of tau protein inclusions and amyloid beta (A beta) plaques in the brain, with A beta peptides generated by cleavage of the amyloid precursor protein (APP) by BACE1 and gamma-secretase. We previously described a primary rat neuron assay in which tau inclusions form from endogenous rat tau after seeding cells with insoluble tau isolated from the human AD brain. Here, we used this assay to screen an annotated library of similar to 8700 biologically active small molecules for their ability to reduce immunostained neuronal tau inclusions. Compounds causing >= 30% inhibition of tau aggregates with <25% loss of DAPI-positive cell nuclei underwent further confirmation testing and assessment of neurotoxicity, and non-neurotoxic hits were subsequently analyzed for inhibitory activity in an orthogonal ELISA that quantified multimeric rat tau species. Of the 173 compounds meeting all criteria, a subset of 55 inhibitors underwent concentration -response testing and 46 elicited a concentrationdependent reduction of neuronal tau inclusions that were distinct from measures of toxicity. Among the confirmed inhibitors of tau pathology were BACE1 inhibitors, several of which, along with gamma-secretase inhibitors/modulators, caused a concentration -dependent lowering of neuronal tau inclusions and a reduction of insoluble tau by immunoblotting, although they did not decrease soluble phosphorylated tau species. In conclusion, we have identified a diverse set of small molecules and related targets that reduce neuronal tau inclusions. Notably, these include BACE1 and gamma-secretase inhibitors, suggesting that a cleavage product from a shared substrate, such as APP, might affect tau pathology.